News | October 22, 2007

Osteoporosis Imaging to Predict Heart Attacks, Stroke

October 23, 2007 - Hologic Inc. today announced that a study has been published online in the Journal of Bone and Mineral Research that used single-energy vertebral fracture assessment (VFA) exams to measure abdominal aortic calcification, concluding that “…a high level of abdominal aortic calcification (AAC) detected on VFA images is predictive of incident myocardial infarction or stroke among elderly Caucasian women, independent of other clinical CVD (cardiovascular disease) risk factors.”

The study, titled "Abdominal Aortic Calcification Detected on Lateral Spine Images from a Bone Densitometer Predicts Incident Myocardial Infarction or Stroke in Older Women," indicates that physicians should use the opportunity of a VFA scan to look for evidence of cardiovascular disease.

“Previous work has shown that it is cost effective to do VFA scans in many postmenopausal women to detect vertebral fracture, and prescribe osteoporosis treatment medication when such a vertebral fracture is seen.” says lead author, John Schousboe, M.D. of Park Nicollet Health Services in Minneapolis, MN. “This is particularly important in women, since two-thirds of women who died suddenly of coronary heart disease have no prior symptoms.”

“This study found that AAC had a similar predictive strength for cardiovascular disease (CVD) as the Framingham Point score. The Framingham Point score combines the traditional risk factors of total cholesterol, HDL, blood pressure, hypertension treatment and smoking to predict 10-year cardiovascular heart disease risk” says co-author Eugene McCloskey, M.D., of Sheffield University, UK. “Additionally, we found that this predictive ability of AAC was independent of the all of the traditional CVD risk factors we collected in the study.”

For more information: www.hologic.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now